Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sarecycline - Almirall S.A./Paratek Pharmaceuticals

Drug Profile

Sarecycline - Almirall S.A./Paratek Pharmaceuticals

Alternative Names: P 0005672; P 005672; Seysara; WC-3035

Latest Information Update: 23 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Actavis; Almirall S.A.; Paratek Pharmaceuticals
  • Class Amides; Antiacnes; Antibacterials; Naphthacenes; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Acne vulgaris

Highest Development Phases

  • Marketed Acne vulgaris
  • No development reported Rosacea

Most Recent Events

  • 18 Jan 2019 Launched for Acne vulgaris (In adolescents, In children, In adults) in USA (PO) - First global launch
  • 17 Jan 2019 Additional safety and efficacy data from the two phase III trial in Acne vulgaris released by Almirall
  • 31 Oct 2018 Almirall plans to launch drug in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top